Andere talen SK Biopharmaceuticals Co., Ltd.

Aandelen

A326030

KR7326030004

slotkoers Korea S.E. Andere beurzen 00:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
83.500 ^KRW	+0,24%		-1,07%	-16,83%

30/01	SK Biopharmaceuticals boekt winst in het vierde kwartaal	MT
2023	SK Biopharmaceuticals' Proteovant Therapeutics presenteert preklinische gegevens op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

SK Life Science - XCOPRI CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube	12/04
SK Life Science Celebrates Purple Day Highlighting Partnerships and Tools Designed to Empower People Living with Epilepsy in Their Journey to Achieve Zero Seizures	26/03
SK Biopharmaceuticals Swings to Profit in Q4	30/01
SK Group Advances Net Zero Transition via Key Renewable Energy Deal	27/11
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	12-10-23
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference	27-09-23
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd..	31-08-23
Hikma and SK Biopharmaceuticals enter a strategic partnership for the Middle East and North Africa	21-08-23
South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2%	21-08-23
SK Biopharmaceuticals Enters Licensing Agreement with Hikma's Middle East Division	21-08-23
SK Biopharmaceuticals Continues to Report Losses in Q2	11-08-23
SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation	03-08-23
SK Biopharmaceuticals Forecasts $1 Billion in US Sales by 2029	19-07-23
SK Biopharmaceuticals Co., Ltd. agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. for $47.5 million.	30-06-23
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
SK Biopharmaceuticals Narrows Loss in Q1	12-05-23
SK Biopharmaceuticals Swings to Loss in Q4	09-02-23
SK to Showcase 40 Carbon Reduction Technologies at CES 2023	21-12-22
SK Biopharmaceuticals' Anti-Epilepsy Treatment Cenobamate Approve for Sale in France	12-12-22
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France	09-12-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SK Biopharmaceuticals Co., Ltd.

Aandelen

A326030

KR7326030004

Andere talen

Filters